Perjeta (pertuzumab)

pCPA File Number: 21742
Negotiation Status:
Active Negotiation
Indication(s):
In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive)
Sponsor/Manufacturer:
HOFFMANN-LA ROCHE LIMITED 
CADTH Project Number:
PC0241
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable